Company intelligence / Profile preview

AALU

Seongnam, Gyeonggi, South Korea

Ownership: Private
Development stage: Other

Overview

AL Biotech is a South Korean biopharmaceutical company founded in 2021 that specializes in the development of novel therapeutics for incurable diseases, with a primary focus on oncology. The company leverages a proprietary platform for immuno-anticancer drug cultivation, utilizing advanced modalities such as bispecific antibodies and antibody fragments. Their research aims to provide clinicians with innovative tools to treat complex cancers by enhancing the body's immune response. In March 2025, the company was acquired by Vaxcell-Bio Therapeutics, a move intended to accelerate the advancement of its drug development pipeline. AL Biotech is headquartered in the biotech hub of Seongnam, South Korea.

Therapeutic areas: OncologyRare Diseases
Modalities: AntibodyBispecific monoclonal antibodyMonoclonal antibody fragment
Industry: Biotech

Beyond the preview

Go deeper on AALU.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AALU.

Explore the full profile